IRulya Therapeutics Inc.
IRLAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 9, 2026 | Raymond James | $72.00(+145%) | $29.36 | TheFly | |
| Aug 20, 2026 | Craig-Hallum | $68.00(+97%) | $34.57 | TheFly | |
| Aug 18, 2026 | Cantor Fitzgerald | Olivia Brayer Saunders | $70.00(+113%) | $32.91 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citizens | upgrade | Market Perform →Market Outperform | Sep 22, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Aug 18, 2026 |
| Oppenheimer | maintain | Outperform | Jul 29, 2026 |
| Credit Suisse | maintain | Underperform | May 10, 2022 |
| HC Wainwright & Co. | maintain | Buy | Mar 8, 2022 |
| Canaccord Genuity | downgrade | Buy →Hold | Jan 27, 2022 |
| JMP Securities | downgrade | Market Outperform →Perform | Jan 27, 2022 |
| JMP Securities | downgrade | Market Outperform →Market Perform | Jan 26, 2022 |
| B of A Securities | downgrade | Neutral →Underperform | Oct 26, 2021 |
| HC Wainwright & Co. | maintain | Buy | Oct 26, 2021 |
| Canaccord Genuity | maintain | Buy | Sep 15, 2021 |
| HC Wainwright & Co. | maintain | Buy | Aug 25, 2021 |
| Jefferies | downgrade | Buy →Hold | Feb 16, 2021 |
| B of A Securities | upgrade | Neutral →Buy | Dec 6, 2020 |
| Ladenburg Thalmann | downgrade | Buy →Neutral | Sep 16, 2013 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-1.39| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-12.31 | $-28.02 | — | — |
| May 12, 2026 | $75.60 | $-26.00 | — | — |
| Apr 6, 2026 | $-3.50 | $-3.59 | — | — |
| Nov 12, 2025 | $-50.00 | $-40.00 | — | — |
| Aug 11, 2025 | $-68.00 | $-56.00 | — | — |
| May 13, 2025 | $-68.00 | $-48.00 | — | — |
| Mar 24, 2025 | $-56.00 | $-38.00 | — | — |
| Nov 13, 2024 | $-26.00 | $-34.67 | — | — |
News
NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapeutics for serious underserved diseases, today announced that senior management will participate in a Fireside Chat at the Craig-Hallum Biotech Catalyst Conference on Thursday, October 22, 2026.
What happened Quince Therapeutics, Inc. (NASDAQ: QNCX) said it changed its name to IRulya Therapeutics Inc. effective at 4:01 p.m. Eastern Time on October 9, 2026. The common stock is expected to begin trading on the Nasdaq Capital Market under IRLA on October 12, 2026. The filing says Brigette Roberts, M.D., became chief executive officer
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R.
Quince Therapeutics (NASDAQ: QNCX) stockholders approved five proposals at the company's Oct. 6, 2026 special meeting, including measures related to the conversion of preferred stock, a private investment in public equity transaction, an increase in authorized common shares, and new equity compensation plans. Dirk Thye, Quince's Chief Executive Officer and Chief Medical Officer, called the virtual
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026:
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline